June 1, 2017
BioMarin cleared in EU for TPP1 deficiency treatment
BioMarin Pharmaceuticalsaid today that it got from the European Commission (EC) a grant for Brineura (cerliponase alfa), the first treatment approved in the European Union (EU) for tripeptidyl peptidase 1 (TPP1) deficiency.